How to resist PI3Kδ inhibition: activate MAPK!

被引：1
|
作者：
Okkenhaug, Klaus [1 ]
机构：
[1] Univ Cambridge, Cambridge, England
来源：
BLOOD | 2021年 / 138卷 / 01期
关键词：
IDELALISIB; RITUXIMAB;
D O I：
10.1182/blood.2021011365
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In this issue of Blood, Murali et al report that activation of the MAPK pathway can compensate for loss of PI3K signaling in patients with CLL who did not respond to treatment with idelalisib.
引用
收藏
页码：3 / 4
页数：2
相关论文
共 50 条
  • [1] It Takes Two to Tango: Dual Inhibition of PI3K and MAPK in Rhabdomyosarcoma
    Jahangiri, Arman
    Weiss, William A.
    [J]. CLINICAL CANCER RESEARCH, 2013, 19 (21) : 5811 - 5813
  • [2] A Bifunctional MAPK/PI3K Antagonist for Inhibition of Tumor Growth and Metastasis
    Galban, Stefanie
    Apfelbaum, April A.
    Espinoza, Carlos
    Heist, Kevin
    Haley, Henry
    Bedi, Karan
    Ljungman, Mats
    Galban, Craig J.
    Luker, Gary D.
    Van Dort, Marcian
    Ross, Brian D.
    [J]. MOLECULAR CANCER THERAPEUTICS, 2017, 16 (11) : 2340 - 2350
  • [3] Irradiation and targeted inhibition of the PI3K/AKT and MAPK pathways in glioma
    Sminia, P.
    Narayan, R.
    Gasol, A.
    Cornelissen, F.
    Theys, J.
    Lagerwei, T.
    De Vries, E.
    Bikhezar, F.
    Denkova, A.
    De Kruijff, R.
    Slotman, B.
    Stalpers, L.
    Baumert, B.
    Westerman, B.
    [J]. RADIOTHERAPY AND ONCOLOGY, 2019, 133 : S345 - S346
  • [4] Dual inhibition of MEK/MAPK and PI3K/Akt in multiple myeloma
    Steinbrunn, T.
    Stuehmer, T.
    Sayehli, C.
    Chatterjee, M.
    Einsele, H.
    Bargou, R. C.
    [J]. ONKOLOGIE, 2012, 35 : 140 - 140
  • [5] MAPK and PI3K inhibition reduces proliferation of Barrett's adenocarcinoma in vitro
    Vona-Davis, L
    Frankenberry, K
    Cunningham, C
    Riggs, DR
    Jackson, BJ
    Szwerc, MF
    McFadden, DW
    [J]. JOURNAL OF SURGICAL RESEARCH, 2005, 127 (01) : 53 - 58
  • [6] Synergistic inhibition of thyroid cancer by suppressing MAPK/PI3K/AKT pathways
    Kandil, Emad
    Tsumagari, Koji
    Ma, Jingjing
    Elmageed, Zakaria Y. Abd
    Li, Xinying
    Slakey, Douglas
    Mondal, Debasis
    Abdel-Mageed, Asim B.
    [J]. JOURNAL OF SURGICAL RESEARCH, 2013, 184 (02) : 898 - 906
  • [7] Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition
    Kim, H. S.
    Jung, M.
    Kang, H. N.
    Kim, H.
    Park, C-W
    Kim, S-M
    Shin, S. J.
    Kim, S. H.
    Kim, S. G.
    Kim, E. K.
    Yun, M. R.
    Zheng, Z.
    Chung, K. Y.
    Greenbowe, J.
    Ali, S. M.
    Kim, T-M
    Cho, B. C.
    [J]. ONCOGENE, 2017, 36 (23) : 3334 - 3345
  • [8] MAPK and PI3K activation in esophageal carcinomas
    Michalopoulos, N. V.
    Tasioudi, K. E.
    Sakellariou, S.
    Levidou, G.
    Kontogianni, P.
    Theodorou, D.
    Korkolopoulou, P.
    Patsouris, E.
    Saetta, A.
    [J]. EUROPEAN JOURNAL OF CANCER, 2013, 49 : S159 - S159
  • [9] Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition
    H S Kim
    M Jung
    H N Kang
    H Kim
    C-W Park
    S-M Kim
    S J Shin
    S H Kim
    S G Kim
    E K Kim
    M R Yun
    Z Zheng
    K Y Chung
    J Greenbowe
    S M Ali
    T-M Kim
    B C Cho
    [J]. Oncogene, 2017, 36 : 3334 - 3345
  • [10] Does Ras Activate Raf and PI3K Allosterically?
    Nussinov, Ruth
    Tsai, Chung-Jung
    Jang, Hyunbum
    [J]. FRONTIERS IN ONCOLOGY, 2019, 9
12345